Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET
- Citation:
- Blood vol 117 (20) 5314-5320
- Year:
- 2011
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 360
- Children:
- None
- Pharmas:
- Grants:
- U10 CA032291, CA33601, CA77597, CA04457, U10 CA077658, CA77406, CA32291, CA29165, CA41287, CA03927, U10 CA031946, CA77651, U10 CA033601, CA59518, CA60138, CA26806, CA45389, U10 CA077597, CA45808, CA86726, U10 CA077440, CA77440, U10 CA077651, CA21060, CA47559, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31983, CA31946, CA07968
- Corr. Author:
- Authors:
- David J. Straus Jeffrey L. Johnson Ann S. LaCasce Nancy L. Bartlett Lale Kostakoglu Eric D. Hsi Heiko Schöder Nathan C. Hall Sin-Ho Jung George P. Canellos Lawrence H. Schwartz Ronald W. Takvorian Malik E. Juweid Bruce D. Cheson
- Networks:
- Study
- CALGB-50203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Clinical Trials and Observations, Lymphoid Neoplasia